A subset of lung cancer cells with EGFR or BRG1 mutations shows selective sensitivity to a combination of EZH2 inhibitors with topoisomerase II inhibitors such as the commonly used chemotherapeutic drug etoposide.
- Christine M. Fillmore
- Chunxiao Xu
- Carla F. Kim
